BDX · 10-Q · 2026Q2 · Full report

Revenue Performance and Mix

BECTON DICKINSON & CO · 2026-08-06 · Importance 49 · Surprise 32 · No source text

Third-quarter worldwide revenue increased 5.4%, with volume and other factors contributing 4.1 percentage points. Connected Care benefited from a strong backlog of customer orders in Medication Management Solutions, while Advanced Patient Monitoring revenue grew 10.9% as customers continued adopting Acumen IQ Cuff and Acumen IQ Sensor products. BioPharma Systems reported double-digit growth in prefillable solutions for biologic drugs, led by GLP-1 delivery products, but lower vaccine demand remained a headwind. Interventional demand was strong for oncology products, the Rotarex Atherectomy System, PureWick offerings, infection-prevention products and advanced tissue regeneration products.

Key facts

Worldwide revenues for the three months ended June 30, 2026 were $4.983 billion, an increase of 5.4% from the prior-year period. source
Revenue change for the three months ended June 30, 2026 included Volume/other of 4.1%, Pricing of 0.3%, and Foreign currency impact of 1.0%, totaling a 5.4% increase. source

Impact estimates

metric	direction	stage	expected	basis
revenue	positive	realized	+5.1%	Worldwide revenues for the three months ended June 30, 2026 were $4.983 billion, an increase of 5.4% from the prior-year period.